M014 eosinophilia related to nivolumab: allergy or a helpful ally

Checkpoint inhibitors, as nivolumab, are increasingly relevant in the treatment of several types of cancer. Eosinophilia related to these medications can occur at an estimated frequency of 2.9%. Previous reports suggest eosinophilia is associated to prolonged survival in patients with melanoma receiving nivolumab.

Source: Annals of Allergy, Asthma and Immunology - October 31, 2019 Category: Allergy & Immunology Authors: M. Beltran, I. Carrillo-Martin, Y. Gil, A. Gonzalez-Estrada Source Type: research